{"gene":"TMEM219","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":2016,"finding":"TMEM219 is a direct binding partner of IL-13Rα2, forming a complex that mediates chitinase 3-like-1 (Chi3l1) signaling. Fluorescence anisotropy nanodisc assays confirmed direct physical interaction between TMEM219 and IL-13Rα2-Chi3l1 complexes. Null mutations or siRNA silencing of TMEM219 phenocopied IL-13Rα2 loss, decreasing Chi3l1-stimulated HB-EGF production, MAPK/Erk and PKB/Akt activation, and inhibiting Chi3l1-mediated suppression of oxidant-induced apoptosis and promotion of melanoma metastasis and TGF-β1 stimulation.","method":"Yeast two-hybrid, co-immunoprecipitation, co-localization, bimolecular fluorescence complementation, fluorescence anisotropy nanodisc assays, null mutation and siRNA knockdown with defined phenotypic readouts","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal binding assays including in vitro direct interaction, genetic loss-of-function phenocopying, functional readouts across multiple cell types","pmids":["27629921"],"is_preprint":false},{"year":2011,"finding":"TMEM219 (IGFBP-3R) acts as a receptor for IGFBP-3 and mediates IGF-independent apoptotic signaling: IGFBP-3 binding to IGFBP-3R activates caspases, which degrade IκBα and p65-NF-κB proteins, thereby negatively regulating NF-κB signaling cascades. Knockdown of IGFBP-3R with siRNA completely abolished IGFBP-3's inhibitory effects on NF-κB; non-IGF-binding IGFBP-3 mutants confirmed IGF-independence.","method":"siRNA knockdown, caspase inhibitor experiments, non-IGF-binding IGFBP-3 mutants, in vitro cell-based NF-κB signaling assays, in vivo transgenic mouse model","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (siRNA, caspase inhibitors, non-binding mutants, transgenic mice) establishing receptor-mediated caspase activation and NF-κB degradation","pmids":["21383009"],"is_preprint":false},{"year":2022,"finding":"TMEM219 functions as a death receptor expressed on pancreatic beta cells; its ligand IGFBP-3 signals through TMEM219 to induce beta cell loss and dysfunction. In vitro and in vivo IGFBP-3/TMEM219 inhibition and TMEM219 genetic ablation preserved beta cells, prevented/delayed diabetes onset, and allowed beta cell expansion.","method":"Genetic ablation (TMEM219 knockout), in vitro IGFBP-3/TMEM219 inhibition, in vivo preclinical diabetes models, patient cohort studies with IGFBP-3 measurement","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 — genetic ablation combined with pharmacological inhibition and in vivo diabetes models across multiple systems","pmids":["35115561"],"is_preprint":false},{"year":2024,"finding":"TMEM219 is expressed on pancreatic beta cell precursors and in fetal pancreas; its signaling negatively regulates beta cells at early stages and induces Caspase 8-mediated cell death. Pharmacological blockade of TMEM219 rescued beta cell precursor and proliferation markers and decreased cell death in islets and embryonic-derived endocrine progenitors. miR-129-2 was identified as an endogenous upstream regulator of TMEM219 expression: miR-129-2 mimic downregulated TMEM219, while miR-129-2 inhibitor induced TMEM219 overexpression and restored cell proliferation.","method":"Pharmacological TMEM219 blockade, miRNA mimic/inhibitor experiments, caspase 8 activity assays, in vitro endocrine progenitor differentiation models","journal":"Frontiers in Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2–3 — functional pharmacological blockade and miRNA manipulation with defined molecular readouts, single lab","pmids":["38318298"],"is_preprint":false},{"year":2025,"finding":"TMEM219 mediates intestinal stem cell (ISC) death in Crohn's disease via Caspase-8 activation. Genetic tissue-specific deletion of TMEM219 in ISCs (TMEM219fl/flLGR5cre mice) revived mucosal regenerative abilities in vitro and in vivo. Pharmacological blockade with recombinant ecto-TMEM219 (blocking IGFBP-3/TMEM219 binding) restored self-renewal of ISCs in patient-derived mini-guts and ameliorated colitis in DSS-induced and T cell-mediated models.","method":"Tissue-specific conditional knockout (TMEM219fl/flLGR5cre), pharmacological blockade with ecto-TMEM219, patient-derived organoids (mini-guts), in vivo colitis models, caspase-8 activity assays","journal":"The Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 2 — genetic tissue-specific deletion combined with pharmacological inhibition, patient-derived organoids, and in vivo disease models with defined molecular mechanism (Caspase-8)","pmids":["40371646"],"is_preprint":false},{"year":2013,"finding":"TMEM219 (IGFBP-3R) is required for IGFBP-3-induced apoptosis in lung cancer cells: knockdown of IGFBP-3R hindered IGFBP-3-overexpression-induced NF-κB suppression and apoptosis in tobacco carcinogen-transformed lung epithelial cells.","method":"siRNA knockdown of IGFBP-3R, IGFBP-3 overexpression, NF-κB activity assays, apoptosis assays","journal":"Lung Cancer","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, siRNA knockdown with defined functional readouts confirming receptor requirement","pmids":["23498137"],"is_preprint":false},{"year":2025,"finding":"Monoclonal antibodies blocking IGFBP-3/TMEM219 interaction (anti-TMEM219 mAb Ent001) displaced IGFBP-3/TMEM219 binding, rescued ISC markers and function in patient-derived mini-guts from Crohn's disease patients, downregulated Caspase 8, and improved colitis and prevented inflammatory carcinogenesis in vivo, confirming that direct IGFBP-3/TMEM219 binding is the operative mechanism.","method":"Phage display-generated monoclonal antibodies, binding displacement assays, patient-derived organoids, in vivo DSS colitis and carcinogenesis models","journal":"Pharmacological Research","confidence":"Medium","confidence_rationale":"Tier 2 — antibody displacement of specific receptor-ligand interaction validated in patient organoids and in vivo models","pmids":["40783087"],"is_preprint":false},{"year":2025,"finding":"The IGFBP-3/TMEM219 pathway mediates hepatocyte apoptosis during liver fibrosis progression: IGFBP-3 and TMEM219 gene expression increase coordinately with fibrosis stage, and this is associated with activation of caspase 3/7 and caspase 8 apoptotic pathways in the bile duct ligation rat model.","method":"RT-PCR gene expression analysis, immunofluorescence for caspase 3/7 and caspase 8, histopathology in bile duct ligation rat model","journal":"Molecular Biology Reports","confidence":"Low","confidence_rationale":"Tier 3–4 — correlative gene expression and histopathology without direct manipulation of TMEM219 in this study","pmids":["40853400"],"is_preprint":false}],"current_model":"TMEM219 is a transmembrane death receptor that binds IGFBP-3 (and partners with IL-13Rα2 to transduce Chi3l1 signals), activating Caspase-8-mediated apoptotic cascades in pancreatic beta cells, intestinal stem cells, and other epithelial cell types, while also suppressing NF-κB signaling through caspase-dependent degradation of IκBα and p65; blockade of IGFBP-3/TMEM219 binding—genetically or pharmacologically—preserves cell viability, promotes tissue regeneration, and ameliorates disease in diabetes and inflammatory bowel disease models."},"narrative":{"teleology":[{"year":2011,"claim":"Identifying TMEM219 as the receptor for IGFBP-3 established that IGFBP-3's IGF-independent apoptotic and NF-κB-suppressive activities converge on a single transmembrane mediator, answering how extracellular IGFBP-3 signals intracellularly.","evidence":"siRNA knockdown, caspase inhibitor experiments, non-IGF-binding IGFBP-3 mutants, and transgenic mice in cell-based NF-κB assays","pmids":["21383009"],"confidence":"High","gaps":["Structural basis of IGFBP-3/TMEM219 binding undefined","Downstream adaptor proteins linking TMEM219 to caspase activation not identified","Tissue-specific expression and function of TMEM219 not yet explored"]},{"year":2013,"claim":"Demonstrating that TMEM219 knockdown blocked IGFBP-3-induced apoptosis in carcinogen-transformed lung epithelial cells extended the receptor's functional relevance beyond the original cell systems.","evidence":"siRNA knockdown of IGFBP-3R with IGFBP-3 overexpression, NF-κB and apoptosis readouts in lung cancer cells","pmids":["23498137"],"confidence":"Medium","gaps":["Single lab, single cell type; independent replication in additional cancer models lacking","Whether TMEM219 expression level predicts IGFBP-3 sensitivity in tumors untested"]},{"year":2016,"claim":"Discovery that TMEM219 physically interacts with IL-13Rα2 to transduce Chi3l1 signals revealed an unexpected second ligand-receptor axis for TMEM219, showing it participates in pro-survival MAPK/Erk and Akt signaling in addition to its pro-apoptotic IGFBP-3 function.","evidence":"Yeast two-hybrid, co-IP, bimolecular fluorescence complementation, fluorescence anisotropy nanodisc assays, null mutations and siRNA phenocopying","pmids":["27629921"],"confidence":"High","gaps":["How TMEM219 integrates opposing pro-apoptotic (IGFBP-3) and pro-survival (Chi3l1) signals is unresolved","Stoichiometry and structure of the TMEM219/IL-13Rα2/Chi3l1 complex unknown","Relative dominance of each pathway in shared tissue contexts not tested"]},{"year":2022,"claim":"Genetic ablation and pharmacological blockade of TMEM219 in pancreatic beta cells prevented diabetes onset and enabled beta cell expansion, establishing TMEM219 as a death receptor governing beta cell homeostasis and identifying it as a therapeutic target in diabetes.","evidence":"TMEM219 knockout mice, in vitro and in vivo IGFBP-3/TMEM219 inhibition, preclinical diabetes models, patient cohort IGFBP-3 measurements","pmids":["35115561"],"confidence":"High","gaps":["Precise intracellular signaling intermediates between TMEM219 and Caspase-8 in beta cells not fully mapped","Long-term safety of TMEM219 blockade on beta cell neoplasia risk unassessed"]},{"year":2024,"claim":"Identification of miR-129-2 as an upstream regulator of TMEM219 expression, and demonstration that TMEM219 signals through Caspase-8 in beta cell precursors, added a transcriptional regulatory layer and extended the pathway to developmental stages of the endocrine pancreas.","evidence":"miRNA mimic/inhibitor experiments, caspase-8 activity assays, pharmacological TMEM219 blockade in endocrine progenitor differentiation models","pmids":["38318298"],"confidence":"Medium","gaps":["miR-129-2 regulation demonstrated in a single lab system; confirmation in vivo needed","Whether additional miRNAs or transcription factors regulate TMEM219 in other tissues is unknown"]},{"year":2025,"claim":"Tissue-specific conditional deletion of TMEM219 in intestinal stem cells and pharmacological blockade with ecto-TMEM219 or anti-TMEM219 monoclonal antibodies restored mucosal regeneration in Crohn's disease organoids and colitis models, confirming IGFBP-3/TMEM219 as the operative death axis in inflammatory bowel disease.","evidence":"TMEM219fl/flLGR5cre conditional knockout, ecto-TMEM219 and monoclonal antibody (Ent001) blockade, patient-derived organoids, DSS and T cell-mediated colitis models","pmids":["40371646","40783087"],"confidence":"High","gaps":["Whether TMEM219 blockade alters intestinal tumor susceptibility long-term remains to be defined","Contribution of Chi3l1/IL-13Rα2 arm of TMEM219 signaling in the intestinal stem cell niche unexplored"]},{"year":null,"claim":"The mechanism by which TMEM219 integrates its two ligand axes (pro-apoptotic IGFBP-3 and pro-survival Chi3l1/IL-13Rα2), the identity of intracellular adaptor proteins linking the receptor to Caspase-8, and the structural determinants of ligand selectivity remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural model of TMEM219 or its ligand-bound complexes exists","Intracellular adaptor(s) bridging TMEM219 cytoplasmic domain to caspase machinery not identified","Tissue-specific contexts determining whether TMEM219 signals death versus survival not systematically mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,2,4]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,2,4]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,2,3,4,5]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1]}],"complexes":[],"partners":["IGFBP3","IL13RA2","CHI3L1","CASP8"],"other_free_text":[]},"mechanistic_narrative":"TMEM219 is a transmembrane death receptor that transduces pro-apoptotic signals in multiple epithelial cell types, functioning through two distinct ligand systems: IGFBP-3 and chitinase 3-like-1 (Chi3l1). Binding of IGFBP-3 to TMEM219 activates Caspase-8-dependent apoptosis in an IGF-independent manner and concurrently suppresses NF-κB signaling through caspase-mediated degradation of IκBα and p65 [PMID:21383009, PMID:23498137]. In pancreatic beta cells and intestinal stem cells, IGFBP-3/TMEM219 signaling drives cell death and tissue loss; genetic ablation or pharmacological blockade of this interaction preserves cell viability, promotes regeneration, and ameliorates diabetes and colitis in preclinical models [PMID:35115561, PMID:40371646, PMID:40783087]. TMEM219 also forms a complex with IL-13Rα2 to mediate Chi3l1-stimulated MAPK/Erk and Akt activation, HB-EGF production, and suppression of oxidant-induced apoptosis [PMID:27629921]."},"prefetch_data":{"uniprot":{"accession":"Q86XT9","full_name":"Insulin-like growth factor-binding protein 3 receptor","aliases":["Transmembrane protein 219"],"length_aa":240,"mass_kda":25.7,"function":"Cell death receptor specific for IGFBP3, may mediate caspase-8-dependent apoptosis upon ligand binding","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q86XT9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TMEM219","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TMEM219","total_profiled":1310},"omim":[{"mim_id":"620290","title":"TRANSMEMBRANE PROTEIN 219; TMEM219","url":"https://www.omim.org/entry/620290"},{"mim_id":"615851","title":"PONTOCEREBELLAR HYPOPLASIA, TYPE 2E; PCH2E","url":"https://www.omim.org/entry/615851"},{"mim_id":"615850","title":"VPS53 SUBUNIT OF GARP COMPLEX; VPS53","url":"https://www.omim.org/entry/615850"},{"mim_id":"300130","title":"INTERLEUKIN 13 RECEPTOR, ALPHA-2; IL13RA2","url":"https://www.omim.org/entry/300130"},{"mim_id":"146732","title":"INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 3; IGFBP3","url":"https://www.omim.org/entry/146732"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TMEM219"},"hgnc":{"alias_symbol":["IGFBP-3R"],"prev_symbol":[]},"alphafold":{"accession":"Q86XT9","domains":[{"cath_id":"-","chopping":"54-179","consensus_level":"high","plddt":66.6779,"start":54,"end":179},{"cath_id":"1.10.287","chopping":"19-45_194-226","consensus_level":"high","plddt":83.8982,"start":19,"end":226}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86XT9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q86XT9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q86XT9-F1-predicted_aligned_error_v6.png","plddt_mean":67.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TMEM219","jax_strain_url":"https://www.jax.org/strain/search?query=TMEM219"},"sequence":{"accession":"Q86XT9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q86XT9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q86XT9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86XT9"}},"corpus_meta":[{"pmid":"27629921","id":"PMC_27629921","title":"IL-13Rα2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27629921","citation_count":115,"is_preprint":false},{"pmid":"21383009","id":"PMC_21383009","title":"Insulin-like growth factor-binding protein-3 (IGFBP-3) blocks the effects of asthma by negatively regulating NF-κB signaling through IGFBP-3R-mediated activation of caspases.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21383009","citation_count":67,"is_preprint":false},{"pmid":"35115561","id":"PMC_35115561","title":"The IGFBP3/TMEM219 pathway regulates beta cell homeostasis.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35115561","citation_count":47,"is_preprint":false},{"pmid":"23498137","id":"PMC_23498137","title":"Tobacco specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone suppresses a newly identified anti-tumor IGFBP-3/IGFBP-3R system in lung cancer cells.","date":"2013","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/23498137","citation_count":17,"is_preprint":false},{"pmid":"38318298","id":"PMC_38318298","title":"TMEM219 regulates the transcription factor expression and proliferation of beta cells.","date":"2024","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/38318298","citation_count":9,"is_preprint":false},{"pmid":"40447257","id":"PMC_40447257","title":"Xanthosomes loaded with recombinant TMEM219 for targeting IGFBP-3: A novel approach for targeted drug delivery to ameliorate liver fibrosis.","date":"2025","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40447257","citation_count":4,"is_preprint":false},{"pmid":"40371646","id":"PMC_40371646","title":"TMEM219 signaling promotes intestinal stem cell death and exacerbates colitis.","date":"2025","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/40371646","citation_count":3,"is_preprint":false},{"pmid":"40783087","id":"PMC_40783087","title":"Targeting of the IGFBP3/TMEM219 pathway restores intestinal stem cells capability of healing mucosa in gastrointestinal autoimmune disorders.","date":"2025","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/40783087","citation_count":1,"is_preprint":false},{"pmid":"40371644","id":"PMC_40371644","title":"Promoting mucosal healing by targeting TMEM219-dependent intestinal epithelial stem cell defects in inflammatory bowel disease.","date":"2025","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/40371644","citation_count":0,"is_preprint":false},{"pmid":"40853400","id":"PMC_40853400","title":"Stage-specific role of IGFBP-3/TMEM219 pathway in liver fibrosis progression using a bile duct ligation rat model.","date":"2025","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/40853400","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":6749,"output_tokens":2479,"usd":0.028716},"stage2":{"model":"claude-opus-4-6","input_tokens":5813,"output_tokens":2201,"usd":0.126135},"total_usd":0.154851,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"TMEM219 is a direct binding partner of IL-13Rα2, forming a complex that mediates chitinase 3-like-1 (Chi3l1) signaling. Fluorescence anisotropy nanodisc assays confirmed direct physical interaction between TMEM219 and IL-13Rα2-Chi3l1 complexes. Null mutations or siRNA silencing of TMEM219 phenocopied IL-13Rα2 loss, decreasing Chi3l1-stimulated HB-EGF production, MAPK/Erk and PKB/Akt activation, and inhibiting Chi3l1-mediated suppression of oxidant-induced apoptosis and promotion of melanoma metastasis and TGF-β1 stimulation.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, co-localization, bimolecular fluorescence complementation, fluorescence anisotropy nanodisc assays, null mutation and siRNA knockdown with defined phenotypic readouts\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal binding assays including in vitro direct interaction, genetic loss-of-function phenocopying, functional readouts across multiple cell types\",\n      \"pmids\": [\"27629921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TMEM219 (IGFBP-3R) acts as a receptor for IGFBP-3 and mediates IGF-independent apoptotic signaling: IGFBP-3 binding to IGFBP-3R activates caspases, which degrade IκBα and p65-NF-κB proteins, thereby negatively regulating NF-κB signaling cascades. Knockdown of IGFBP-3R with siRNA completely abolished IGFBP-3's inhibitory effects on NF-κB; non-IGF-binding IGFBP-3 mutants confirmed IGF-independence.\",\n      \"method\": \"siRNA knockdown, caspase inhibitor experiments, non-IGF-binding IGFBP-3 mutants, in vitro cell-based NF-κB signaling assays, in vivo transgenic mouse model\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (siRNA, caspase inhibitors, non-binding mutants, transgenic mice) establishing receptor-mediated caspase activation and NF-κB degradation\",\n      \"pmids\": [\"21383009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TMEM219 functions as a death receptor expressed on pancreatic beta cells; its ligand IGFBP-3 signals through TMEM219 to induce beta cell loss and dysfunction. In vitro and in vivo IGFBP-3/TMEM219 inhibition and TMEM219 genetic ablation preserved beta cells, prevented/delayed diabetes onset, and allowed beta cell expansion.\",\n      \"method\": \"Genetic ablation (TMEM219 knockout), in vitro IGFBP-3/TMEM219 inhibition, in vivo preclinical diabetes models, patient cohort studies with IGFBP-3 measurement\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic ablation combined with pharmacological inhibition and in vivo diabetes models across multiple systems\",\n      \"pmids\": [\"35115561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TMEM219 is expressed on pancreatic beta cell precursors and in fetal pancreas; its signaling negatively regulates beta cells at early stages and induces Caspase 8-mediated cell death. Pharmacological blockade of TMEM219 rescued beta cell precursor and proliferation markers and decreased cell death in islets and embryonic-derived endocrine progenitors. miR-129-2 was identified as an endogenous upstream regulator of TMEM219 expression: miR-129-2 mimic downregulated TMEM219, while miR-129-2 inhibitor induced TMEM219 overexpression and restored cell proliferation.\",\n      \"method\": \"Pharmacological TMEM219 blockade, miRNA mimic/inhibitor experiments, caspase 8 activity assays, in vitro endocrine progenitor differentiation models\",\n      \"journal\": \"Frontiers in Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — functional pharmacological blockade and miRNA manipulation with defined molecular readouts, single lab\",\n      \"pmids\": [\"38318298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TMEM219 mediates intestinal stem cell (ISC) death in Crohn's disease via Caspase-8 activation. Genetic tissue-specific deletion of TMEM219 in ISCs (TMEM219fl/flLGR5cre mice) revived mucosal regenerative abilities in vitro and in vivo. Pharmacological blockade with recombinant ecto-TMEM219 (blocking IGFBP-3/TMEM219 binding) restored self-renewal of ISCs in patient-derived mini-guts and ameliorated colitis in DSS-induced and T cell-mediated models.\",\n      \"method\": \"Tissue-specific conditional knockout (TMEM219fl/flLGR5cre), pharmacological blockade with ecto-TMEM219, patient-derived organoids (mini-guts), in vivo colitis models, caspase-8 activity assays\",\n      \"journal\": \"The Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic tissue-specific deletion combined with pharmacological inhibition, patient-derived organoids, and in vivo disease models with defined molecular mechanism (Caspase-8)\",\n      \"pmids\": [\"40371646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TMEM219 (IGFBP-3R) is required for IGFBP-3-induced apoptosis in lung cancer cells: knockdown of IGFBP-3R hindered IGFBP-3-overexpression-induced NF-κB suppression and apoptosis in tobacco carcinogen-transformed lung epithelial cells.\",\n      \"method\": \"siRNA knockdown of IGFBP-3R, IGFBP-3 overexpression, NF-κB activity assays, apoptosis assays\",\n      \"journal\": \"Lung Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, siRNA knockdown with defined functional readouts confirming receptor requirement\",\n      \"pmids\": [\"23498137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Monoclonal antibodies blocking IGFBP-3/TMEM219 interaction (anti-TMEM219 mAb Ent001) displaced IGFBP-3/TMEM219 binding, rescued ISC markers and function in patient-derived mini-guts from Crohn's disease patients, downregulated Caspase 8, and improved colitis and prevented inflammatory carcinogenesis in vivo, confirming that direct IGFBP-3/TMEM219 binding is the operative mechanism.\",\n      \"method\": \"Phage display-generated monoclonal antibodies, binding displacement assays, patient-derived organoids, in vivo DSS colitis and carcinogenesis models\",\n      \"journal\": \"Pharmacological Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody displacement of specific receptor-ligand interaction validated in patient organoids and in vivo models\",\n      \"pmids\": [\"40783087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The IGFBP-3/TMEM219 pathway mediates hepatocyte apoptosis during liver fibrosis progression: IGFBP-3 and TMEM219 gene expression increase coordinately with fibrosis stage, and this is associated with activation of caspase 3/7 and caspase 8 apoptotic pathways in the bile duct ligation rat model.\",\n      \"method\": \"RT-PCR gene expression analysis, immunofluorescence for caspase 3/7 and caspase 8, histopathology in bile duct ligation rat model\",\n      \"journal\": \"Molecular Biology Reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3–4 — correlative gene expression and histopathology without direct manipulation of TMEM219 in this study\",\n      \"pmids\": [\"40853400\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TMEM219 is a transmembrane death receptor that binds IGFBP-3 (and partners with IL-13Rα2 to transduce Chi3l1 signals), activating Caspase-8-mediated apoptotic cascades in pancreatic beta cells, intestinal stem cells, and other epithelial cell types, while also suppressing NF-κB signaling through caspase-dependent degradation of IκBα and p65; blockade of IGFBP-3/TMEM219 binding—genetically or pharmacologically—preserves cell viability, promotes tissue regeneration, and ameliorates disease in diabetes and inflammatory bowel disease models.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TMEM219 is a transmembrane death receptor that transduces pro-apoptotic signals in multiple epithelial cell types, functioning through two distinct ligand systems: IGFBP-3 and chitinase 3-like-1 (Chi3l1). Binding of IGFBP-3 to TMEM219 activates Caspase-8-dependent apoptosis in an IGF-independent manner and concurrently suppresses NF-κB signaling through caspase-mediated degradation of IκBα and p65 [PMID:21383009, PMID:23498137]. In pancreatic beta cells and intestinal stem cells, IGFBP-3/TMEM219 signaling drives cell death and tissue loss; genetic ablation or pharmacological blockade of this interaction preserves cell viability, promotes regeneration, and ameliorates diabetes and colitis in preclinical models [PMID:35115561, PMID:40371646, PMID:40783087]. TMEM219 also forms a complex with IL-13Rα2 to mediate Chi3l1-stimulated MAPK/Erk and Akt activation, HB-EGF production, and suppression of oxidant-induced apoptosis [PMID:27629921].\",\n  \"teleology\": [\n    {\n      \"year\": 2011,\n      \"claim\": \"Identifying TMEM219 as the receptor for IGFBP-3 established that IGFBP-3's IGF-independent apoptotic and NF-κB-suppressive activities converge on a single transmembrane mediator, answering how extracellular IGFBP-3 signals intracellularly.\",\n      \"evidence\": \"siRNA knockdown, caspase inhibitor experiments, non-IGF-binding IGFBP-3 mutants, and transgenic mice in cell-based NF-κB assays\",\n      \"pmids\": [\"21383009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of IGFBP-3/TMEM219 binding undefined\",\n        \"Downstream adaptor proteins linking TMEM219 to caspase activation not identified\",\n        \"Tissue-specific expression and function of TMEM219 not yet explored\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that TMEM219 knockdown blocked IGFBP-3-induced apoptosis in carcinogen-transformed lung epithelial cells extended the receptor's functional relevance beyond the original cell systems.\",\n      \"evidence\": \"siRNA knockdown of IGFBP-3R with IGFBP-3 overexpression, NF-κB and apoptosis readouts in lung cancer cells\",\n      \"pmids\": [\"23498137\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single lab, single cell type; independent replication in additional cancer models lacking\",\n        \"Whether TMEM219 expression level predicts IGFBP-3 sensitivity in tumors untested\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Discovery that TMEM219 physically interacts with IL-13Rα2 to transduce Chi3l1 signals revealed an unexpected second ligand-receptor axis for TMEM219, showing it participates in pro-survival MAPK/Erk and Akt signaling in addition to its pro-apoptotic IGFBP-3 function.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, bimolecular fluorescence complementation, fluorescence anisotropy nanodisc assays, null mutations and siRNA phenocopying\",\n      \"pmids\": [\"27629921\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How TMEM219 integrates opposing pro-apoptotic (IGFBP-3) and pro-survival (Chi3l1) signals is unresolved\",\n        \"Stoichiometry and structure of the TMEM219/IL-13Rα2/Chi3l1 complex unknown\",\n        \"Relative dominance of each pathway in shared tissue contexts not tested\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Genetic ablation and pharmacological blockade of TMEM219 in pancreatic beta cells prevented diabetes onset and enabled beta cell expansion, establishing TMEM219 as a death receptor governing beta cell homeostasis and identifying it as a therapeutic target in diabetes.\",\n      \"evidence\": \"TMEM219 knockout mice, in vitro and in vivo IGFBP-3/TMEM219 inhibition, preclinical diabetes models, patient cohort IGFBP-3 measurements\",\n      \"pmids\": [\"35115561\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Precise intracellular signaling intermediates between TMEM219 and Caspase-8 in beta cells not fully mapped\",\n        \"Long-term safety of TMEM219 blockade on beta cell neoplasia risk unassessed\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of miR-129-2 as an upstream regulator of TMEM219 expression, and demonstration that TMEM219 signals through Caspase-8 in beta cell precursors, added a transcriptional regulatory layer and extended the pathway to developmental stages of the endocrine pancreas.\",\n      \"evidence\": \"miRNA mimic/inhibitor experiments, caspase-8 activity assays, pharmacological TMEM219 blockade in endocrine progenitor differentiation models\",\n      \"pmids\": [\"38318298\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"miR-129-2 regulation demonstrated in a single lab system; confirmation in vivo needed\",\n        \"Whether additional miRNAs or transcription factors regulate TMEM219 in other tissues is unknown\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Tissue-specific conditional deletion of TMEM219 in intestinal stem cells and pharmacological blockade with ecto-TMEM219 or anti-TMEM219 monoclonal antibodies restored mucosal regeneration in Crohn's disease organoids and colitis models, confirming IGFBP-3/TMEM219 as the operative death axis in inflammatory bowel disease.\",\n      \"evidence\": \"TMEM219fl/flLGR5cre conditional knockout, ecto-TMEM219 and monoclonal antibody (Ent001) blockade, patient-derived organoids, DSS and T cell-mediated colitis models\",\n      \"pmids\": [\"40371646\", \"40783087\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether TMEM219 blockade alters intestinal tumor susceptibility long-term remains to be defined\",\n        \"Contribution of Chi3l1/IL-13Rα2 arm of TMEM219 signaling in the intestinal stem cell niche unexplored\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The mechanism by which TMEM219 integrates its two ligand axes (pro-apoptotic IGFBP-3 and pro-survival Chi3l1/IL-13Rα2), the identity of intracellular adaptor proteins linking the receptor to Caspase-8, and the structural determinants of ligand selectivity remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No structural model of TMEM219 or its ligand-bound complexes exists\",\n        \"Intracellular adaptor(s) bridging TMEM219 cytoplasmic domain to caspase machinery not identified\",\n        \"Tissue-specific contexts determining whether TMEM219 signals death versus survival not systematically mapped\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 2, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 2, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 2, 3, 4, 5]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"IGFBP3\",\n      \"IL13RA2\",\n      \"CHI3L1\",\n      \"CASP8\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}